Search for a command to run...
Inflammatory Bowel Disease (IBD), encompassing ulcerative colitis and Crohn's disease is a chronic condition involving inflammation of the Gastrointestinal Tract (GIT) characterized by periods of remission and exacerbation. The pathogenesis of IBD involves a complex influence of genetic, environmental, microbial, and immunological factors. Conventional treatments, including corticosteroids, immunosuppressants, and biologics, often have significant side effects and do not provide a cure, highlighting the need for alternative therapeutic approaches. Flavonoids, a diverse group of poly-phenolic compounds found in vegetables, fruits, and certain beverages, have garnered significant attention due to their antiinflammatory, antioxidant, and immunomodulatory properties. The present chapter explores the considerable role of flavonoids in the management and treatment of IBD, involving their mechanisms of action, therapeutic benefits, and evidence from preclinical and clinical studies. Key mechanisms by which flavonoids exert their beneficial effects include modulation of inflammatory pathways, inhibition of proinflammatory cytokines, suppression of oxidative stress, and regulation of gut microbiota composition. Preclinical studies using animal models of IBD have demonstrated that flavonoids can mitigate inflammation, decrease disease severity, and improve histopathological outcomes. Clinical trials, although limited, have provided preliminary evidence supporting the efficacy of flavonoid supplementation in reducing clinical manifestations and inflammatory markers in IBD patients. Despite the encouraging data, challenges remain regarding the bioavailability, dosage, and longterm safety of flavonoid supplementation. Future research should focus on optimizing delivery methods, elucidating the synergistic effects of flavonoid combinations, and conducting large-scale, well-designed clinical trials to establish standardized guidelines for their use in IBD management. This chapter emphasizes the important role of Epigallocatechin Gallate (EGCG), quercetin, curcumin, and resveratrol in reducing intestinal inflammation and promoting mucosal healing.<br><br>In conclusion, flavonoids represent a promising adjunctive therapy for IBD. Their multifaceted anti-inflammatory and immunomodulatory actions have the potential to improve patient outcomes. Integrating flavonoids into conventional treatment regimens could offer a more holistic approach to managing this debilitating condition.